NasdaqGM - Delayed Quote USD

Avidity Biosciences, Inc. (RNA)

24.36 +0.53 (+2.22%)
At close: April 26 at 4:00 PM EDT
24.36 0.00 (0.00%)
After hours: April 26 at 4:20 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
9,560.00
9,560.00
9,224.00
9,326.00
6,787.00
Operating Expense
245,158.00
245,158.00
188,137.00
127,377.00
51,064.00
Operating Income
-235,598.00
-235,598.00
-178,913.00
-118,051.00
-44,277.00
Net Non Operating Interest Income Expense
23,972.00
23,972.00
4,975.00
104.00
-3.00
Other Income Expense
-594.00
-594.00
-57.00
-62.00
-75.00
Pretax Income
-212,220.00
-212,220.00
-173,995.00
-118,009.00
-44,355.00
Net Income Common Stockholders
-212,220.00
-212,220.00
-173,995.00
-118,009.00
-44,355.00
Diluted NI Available to Com Stockholders
-212,220.00
-212,220.00
-173,995.00
-118,009.00
-44,355.00
Basic EPS
-2.91
--
-3.34
-2.85
-2.05
Diluted EPS
-2.91
--
-3.34
-2.85
-2.05
Basic Average Shares
73,012.00
--
52,162.00
41,428.00
21,663.00
Diluted Average Shares
73,012.00
--
52,162.00
41,428.00
21,663.00
Total Operating Income as Reported
-235,598.00
-235,598.00
-178,913.00
-118,051.00
-44,277.00
Total Expenses
245,158.00
245,158.00
188,137.00
127,377.00
51,064.00
Net Income from Continuing & Discontinued Operation
-212,220.00
-212,220.00
-173,995.00
-118,009.00
-44,355.00
Normalized Income
-212,220.00
-212,220.00
-173,995.00
-118,009.00
-44,355.00
Interest Income
23,972.00
23,972.00
4,975.00
104.00
206.00
Interest Expense
--
--
--
--
209.00
Net Interest Income
23,972.00
23,972.00
4,975.00
104.00
-3.00
EBIT
-235,598.00
-235,598.00
-178,913.00
-118,051.00
-44,146.00
EBITDA
-233,497.00
-233,497.00
-177,526.00
-117,412.00
-43,773.00
Reconciled Depreciation
2,101.00
2,101.00
1,387.00
639.00
373.00
Net Income from Continuing Operation Net Minority Interest
-212,220.00
-212,220.00
-173,995.00
-118,009.00
-44,355.00
Total Unusual Items Excluding Goodwill
--
--
--
--
-75.00
Total Unusual Items
--
--
--
--
-75.00
Normalized EBITDA
-233,497.00
-233,497.00
-177,526.00
-117,412.00
-43,773.00
12/31/2020 - 6/12/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

DYN Dyne Therapeutics, Inc.
24.73
+4.37%
 
FDMT 4D Molecular Therapeutics, Inc.
23.25
-1.19%
 
VERA Vera Therapeutics, Inc.
39.65
+2.48%
 
RVMD Revolution Medicines, Inc.
35.96
+1.78%
 
SANA Sana Biotechnology, Inc.
8.72
+2.59%
 
JANX Janux Therapeutics, Inc.
47.39
+0.62%
 
EWTX Edgewise Therapeutics, Inc.
16.17
+1.44%
 
SYRE Spyre Therapeutics, Inc.
33.56
+3.36%
 
SRRK Scholar Rock Holding Corporation
14.53
+4.08%
 
KURA Kura Oncology, Inc.
19.65
+3.42%